Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Oct 15 - Oct 20
Fitness made for you PT-designed routines and recipes
Because GLP-1 drugs suppress appetite and slow digestion, they can also reduce nutrient intake and alter how nutrients are absorbed
In a commentary on the investment, Gilead chief executive Daniel O'Day said that the company already carries out most of its R&D within the US and has "been increasing our investment in US manufacturing over the last several years, with two large-scale cell therapy sites, and we have additional investment projects underway that are expected to run through 2028." Around $4 billion of the new tranche of funding is earmarked for capital projects, including labs and equipment, with another $5 billion aimed at "technology, operations, and R&D site activities." The remaining $2 billion will be spent on "digital and advanced engineering activities." Gilead expects to create around 800 new jobs from the new funding allocation, with another 2,200 in indirect positions like construction, by 2028
Dozens of new GLP-1 receptor agonist medications are in development across nearly as many firmsand it's not just major pharma names that are getting involved, either
Researchers at the University of Texas Southwestern Medical Center examined medical records from teens and young adults across the country receiving treatment for obesity
US$ 25.98
US$ 29.82
US$ 21.29
US$ 29.00
